Issue 37, 2020

Drug–drug cocrystals of anticancer drugs erlotinib–furosemide and gefitinib–mefenamic acid for alternative multi-drug treatment

Abstract

Drug–drug cocrystals of anticancer drugs erlotinib and gefitinib with furosemide and mefenamic acid, respectively, have been synthesized. The 1 : 1 erlotinib–furosemide cocrystal crystallizes in the monoclinic centrosymmetric P21/n space group containing one molecule of each component in the asymmetric unit. In contrast, the 1 : 1 gefitinib–mefenamic acid cocrystal hydrate belongs to the monoclinic centrosymmetric P21/c space group comprising one molecule of both drugs along with one water molecule in the asymmetric unit. The solubility and dissolution rate study revealed higher solubility for BCS class II drugs, furosemide, and mefenamic acid, while the solubility and dissolution rate of erlotinib showed a significant reduction in the cocrystal salt. Conversely, the solubility of gefitinib didn't reveal a substantial decrease; however, the dissolution rate has been reduced in the cocrystal hydrate. Further, an attempt has been made to correlate the crystal structures of the erlotinib–furosemide and gefitinib–mefenamic acid cocrystals with their solubilities and dissolution rate.

Graphical abstract: Drug–drug cocrystals of anticancer drugs erlotinib–furosemide and gefitinib–mefenamic acid for alternative multi-drug treatment

Supplementary files

Article information

Article type
Paper
Submitted
06 Mar 2020
Accepted
03 Aug 2020
First published
04 Aug 2020

CrystEngComm, 2020,22, 6137-6151

Drug–drug cocrystals of anticancer drugs erlotinib–furosemide and gefitinib–mefenamic acid for alternative multi-drug treatment

C. P. George, S. H. Thorat, P. S. Shaligram, S. P. R. and R. G. Gonnade, CrystEngComm, 2020, 22, 6137 DOI: 10.1039/D0CE00353K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements